证券代码：002433 证券简称：太安堂 编号：2016-10-01 广东太安堂药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------------------|----------------------------|--------------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ 其他 | | | | | 东北证券：崔洁铭、陈亚东、郑晓东、陈婉、覃悦先 | | | 华安基金：陈江玲 | | | | 民生加银基金：金耀 | | | 参与单位名称及人员姓名 | 益菁汇资产管理：刘毅超 | | | | 益研究投资咨询：王沛 | | | | 杭州睿星投资：张文 | | | | 上海顶天投资；解茹、彭大伟 | | | 时间 | 2016 年 10 月 | 20 日下午 3:00-5:00 | | ...

证券代码：002433 证券简称：太安堂 编号：2017-001 广东太安堂药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------------------|----------------------------------|--------------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □其他 | | | 参与单位名称及人员姓名 | | 广证恒生证券投资咨询有限公司：唐爱金 | | | | 上海岳海资产管理公司：方俊、宦璐 | | 时间 | 2017 年 5 月 8 | 日下午 3:30-5:00 | | 地点 | 上海海泰国际大厦 | 25 楼会议室 | | 上市公司接待人员 | 柯少彬、张叶平 | | | | | | | 投资者关系活动 | 问：公司中长期的战略规划是什么？ | | | ...

证券代码：002433 证券简称：太安堂 编号：2016-09-01 广东太安堂药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |------------------------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | □ | 特定对象调研 □分析师会议 | | | | □ | 媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □ | 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | √ 其他 | | | | | | 鼎锋 ...

股票代码：002433 股票简称：太安堂 债券代码：112336 债券简称：16 太安债 编号：2017-002 广东太安堂药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |--------------------|----------------------------------|-------------------------------------------------------------------------------------------------| | | | | | | □ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 √路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | | | 博时基金管理有限公司-刘锴，安信基金管理有限公司- | | 参与单位名称及人员 | | 姜英爱，招商慧合股权投资基金管理有限公司-郭友玲， | | 姓名 | | 深圳市恒泰华盛资产管理有限公司 - 叶颖，中融国际信托 | | | 有限公司 - 宋司筠 | | | 时间 ...

股票代码：002433 股票简称：太安堂 债券代码：112336 债券简称：16 太安债 编号：2017-003 广东太安堂药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------------------|-------------------------------|-----------------------------------| | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | | 招商局资本投资有限责任公司 | - 薛原 | | | 中新融创资本管理有限公司-张芳 | | | | 泰达宏利基金管理有限公司-李更 | | | | | 上海汽车集团股权投资有限公司-吴博 | | 参与单位名称及人员姓名 | 国投财务有限公司-朱靖 | | | | 兴业证券股份有限公司-张枫 | | | | | 中国投融资担保股份有限公司-夏向明 | | | 航天科工财务有限责任公司-韩超 | | | | | ...

股票代码：002433 股票简称：太安堂 债券代码：112336 债券简称：16 太安债 编号：2018-001 广东太安堂药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------------------|------------------------------|--------------------------------------------------------------| | | □ | 特定对象调研 √分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及人员姓名 | | 广州广证恒生证券研究所有限公司—唐爱金 | | 时间 | 2018 年 4 月 17 | 日 15： 30-16：30 | | 地点 | 分析师电话调研 | | | | 总经理—柯少彬 | | | | 副总经理—焦宝元 | | | 上市公司接待人员 | 康爱多常务副总经理—陈彦辉 | | | | 董事会秘书—张叶平 | | | 投 ...

编号：2022-001 证券代码：002433 证券简称：太安堂 广东太安堂药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------------|-------------------------------------------------|----------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | 其他 (2022 | 广东辖区上市公司投资者集体接待日 ) | | 形式 □现场 | 网上 | □电话会议 | | 参与单位名称及人员姓名 | 投资者网上提问 | | | 时间 2022 | 年 9 月 22 | 日（星期四） 15:50-16:50 | | 地点 | 全景网"投资者关系互动平台"（ | https://ir.p5w.net ） | | 上市公司接待人员姓名 | 董事长、总经理、代行董秘：柯少彬 财 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥509,741,466.09, a decrease of 58.87% compared to ¥1,239,408,324.10 in the same period last year[25]. - The net profit attributable to shareholders was -¥113,336,156.13, representing a decline of 121.81% from ¥519,602,162.88 in the previous year[25]. - The net cash flow from operating activities was ¥53,015,804.87, down 87.47% from ¥423,268,140.34 in the same period last year[25]. - The basic and diluted earnings per share were both -¥0.15, a decrease of 122.06% compared to ¥0.68 in the previous year[25]. - The total assets at the end of the reporting period were ¥7,471,254,389.86, a decrease of 2.07% from ¥7,628,958,587.57 at the end of the previous year[25]. - The net assets attributable to shareholders decreased by 2.49% to ¥4,323,245,249.87 from ¥4,433,516,686.71 at the end of the previous year[25]. - The company reported an operating loss of ¥132,535,376.52, a decline of 122.47% year-over-year[38]. - The company's total revenue for the reporting period decreased by ¥729,666,858.01, a decline of 58.87%, mainly due to the significant drop in e-commerce retail sales by its subsidiary[58]. Strategic Focus and Development - The company is focusing on optimizing its strategic and operational layout in the production and sales of traditional Chinese medicine and herbal pieces[33]. - The company is focusing on the development of chronic disease management services, with an expected market size of ¥217.71 billion by 2024[37]. - The company plans to focus on the core business of traditional Chinese medicine R&D and production, while divesting from e-commerce and health industry projects to reduce interest-bearing debt[78]. - The company aims to enhance its internal management and operational efficiency to adapt to market changes and improve risk management capabilities[78]. - The company plans to expand its market presence through new product launches and strategic partnerships in the upcoming quarters[161]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[161]. Risk Management - The management discussion section outlines potential risks and corresponding mitigation strategies, although specific details are not provided in the extracted content[4]. - The company faces risks from policy changes, cost fluctuations in raw materials, and intensified market competition, which may impact profit margins and operational stability[75][76]. - The company emphasizes the importance of investor awareness regarding investment risks associated with future development statements[4]. Corporate Governance and Compliance - The financial report includes a commitment from the board and management to ensure the accuracy and completeness of the financial statements[4]. - The company emphasizes investor rights protection and has improved its governance structure to ensure timely and accurate information disclosure[88]. - The company has not reported any pollution incidents or disputes and has complied with environmental protection laws and regulations[87]. - The company has not experienced any major litigation or arbitration matters during the reporting period[101]. Product and Market Information - The company has 18 production lines for traditional Chinese medicine, with 25 exclusive products, including unique varieties like Qilin Wan and Xin Bao Wan[33]. - The company has invested significantly in product research and development, including the completion of a project for the secondary development of a key traditional Chinese medicine product[39]. - The company has received re-registration approval for three products, indicating progress in its product portfolio[40]. - The company’s unique product "Kirin Pill" is recognized as a national intangible cultural heritage and has received multiple awards for its clinical value[46]. - The company’s proprietary product "Snake Fat Ginseng Yellow Ointment" has received two patents and is recognized for its effectiveness in treating skin conditions[48]. Operational Efficiency - The company has implemented strict quality control measures in production, adhering to the latest GMP standards to enhance product quality[40]. - The company is expanding its sales network through various models, including self-operated, distribution, and e-commerce channels[38]. - The company has established 72 fully automated production lines to enhance product capacity and create technological barriers in traditional Chinese medicine manufacturing[49]. - The company aims to strengthen performance management and improve production efficiency by building smart factories[175]. Financial Strategy - The company's financial strategy involves utilizing bond issuance and bank loans for funding essential operations and development projects[77]. - The company has committed to distributing cash dividends amounting to no less than 30% of the average distributable profit over the next three years, starting from 2022[94]. - The company reported a significant investment loss of CNY 7.45 million in the first half of 2022, compared to a gain of CNY 716.88 million in the same period of 2021[149]. Employee Engagement and Corporate Culture - The company continues to enhance its corporate culture, which has improved employee engagement and overall competitiveness[41]. - The company has established a reasonable compensation and benefits system to enhance employee motivation and creativity[88]. Environmental Responsibility - The company emphasizes environmental protection and energy conservation, aligning with national environmental standards[40]. - The company has not violated any environmental laws in the past three years and has implemented measures to reduce energy consumption and pollution[90]. - The company has increased its tax contributions to the state and local governments, reflecting its commitment to social responsibility[91].

Financial Performance - The company's revenue for Q1 2022 was ¥191,252,969.09, a decrease of 75.35% compared to ¥775,917,621.13 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥37,353,612.37, an improvement of 36.89% from a loss of ¥59,185,352.61 in the previous year[4] - The net profit for the first quarter was a loss of CNY 41,251,302.09, improving from a loss of CNY 66,218,712.44 in the same period last year[26] - The basic and diluted earnings per share improved by 39.11%, increasing by ¥0.03 as the company's losses decreased compared to the previous year[11] - The basic and diluted earnings per share were both reported at -0.05, compared to -0.08 in the previous period[26] Cash Flow - The net cash flow from operating activities was ¥13,460,157.43, down 93.66% from ¥212,283,756.72 in the same period last year[4] - Cash received from sales decreased by ¥653,154,484.82, a decline of 71.87%, primarily due to a significant drop in e-commerce retail sales by subsidiary Guangdong Kangai Digital Health Technology Co., Ltd.[12] - Cash outflow from operating activities decreased by ¥448,975,282.42, a decline of 61.36%, mainly attributed to reduced procurement and VAT from the same subsidiary[13] - The net cash flow from operating activities decreased by ¥198,823,599.31, a decline of 93.66%, primarily due to the same subsidiary's reduced procurement[13] - Cash inflow from financing activities was ¥326,200,000.00, an increase from ¥295,000,000.00 in the previous year[30] - The net cash flow from financing activities was -¥33,730,652.58, compared to -¥259,408,267.27 in Q1 2021, showing an improvement[30] Assets and Liabilities - Total assets decreased by 14.99% to ¥7,546,338,017.06 from ¥8,877,327,761.62 at the end of the previous year[4] - The company's total assets decreased to CNY 7,546,338,017.06 from CNY 7,628,958,587.57[22] - The total liabilities were reported at CNY 3,004,052,136.95, down from CNY 3,044,712,285.51[22] - The equity attributable to shareholders of the parent company was CNY 4,395,453,954.47, slightly down from CNY 4,433,516,686.71[22] Expenses - The company reported a significant reduction in sales expenses by 77.81%, amounting to a decrease of ¥95,064,414.96 due to tightened liquidity[8] - Research and development expenses decreased by 55.69%, reflecting a reduction of ¥2,628,116.76 in investment from the subsidiary Guangdong Kang Aido Digital Health Technology Co., Ltd.[8] - Other income decreased by 55.62%, reflecting a reduction of ¥3,565,607.12 in government subsidies and other non-operating income[9] - The total operating costs amounted to CNY 240,371,640.52, compared to CNY 840,912,104.35 in the prior period[25] Credit and Impairment - The company experienced a 213.93% increase in credit impairment losses, amounting to a decrease of ¥15,056,726.39, due to the recovery of long-aged receivables[9] - The company reported a credit impairment loss of CNY 8,018,556.74, contrasting with a loss of CNY -7,038,169.65 in the prior period[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 103,607[18] - The cash balance at the end of the reporting period was ¥51,854,052.04, down 31.53% from the beginning of the period[20] Investment Activities - Cash inflow from investment activities decreased by ¥11,776,000.00, a decline of 97.94%, due to no investment income being realized during the reporting period[14] - The company did not realize any investment income during the reporting period, leading to a 100% decrease in cash received from investment income[13] - The total cash outflow for investing activities was ¥1,074,446.81, compared to ¥9,099,361.66 in the same period last year[30] Operational Focus - The company continues to focus on cost management and operational efficiency to improve financial performance moving forward[25] - The company’s cash flow from operating activities was significantly impacted, reflecting challenges in revenue generation[29]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2021, representing a year-on-year increase of 15%[18]. - The net profit attributable to shareholders was 150 million RMB, an increase of 10% compared to the previous year[18]. - The company's operating revenue for 2021 was ¥2,264,174,816.08, a decrease of 36.79% compared to ¥3,581,948,583.92 in 2020[23]. - The net profit attributable to shareholders was a loss of ¥803,289,348.21, a decline of 3,714.24% from a profit of ¥22,225,674.49 in 2020[23]. - The total assets at the end of 2021 were ¥7,628,958,587.57, down 15.95% from ¥9,077,058,813.52 at the end of 2020[23]. - The company's basic and diluted earnings per share were both -¥1.05, a decrease of 3,600.00% from ¥0.03 in 2020[23]. - The company reported a significant net loss primarily due to goodwill impairment and losses from asset divestiture[28]. - The company achieved total operating revenue of ¥2,264,174,816.08, a decrease of 36.79% compared to the same period last year[35]. - The operating profit was -¥835,222,061.16, a decline of 2075.50% year-on-year[35]. - The net profit attributable to shareholders was -¥831,921,272.02, a drop of 3193.93% compared to the previous year[35]. Research and Development - The company plans to invest 200 million RMB in research and development for new products and technologies in 2022[18]. - The company invested in R&D, completing projects such as the secondary development of the traditional Chinese medicine Qilin Wan and the IV phase clinical research of a new drug[36]. - The company plans to continue investing in the research and market development of its leading product, Qilin Wan, to capitalize on the growing demand in the reproductive health market[53]. - Research and development (R&D) investment increased by 49.16% year-on-year to CNY 30,400,042.44, representing 1.34% of operating revenue, up from 0.57%[74]. - The company is committed to increasing research and development efforts, including the development of new drug formulations and collaborations with academic institutions[103]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 30% increase in market share within the next three years[18]. - Future guidance estimates a revenue growth of 20% for 2022, driven by new product launches and market expansion efforts[18]. - The company is actively expanding its "Internet + Medicine" business model to enhance user convenience and integrate various healthcare services[44]. - The company aims to improve its industry position through resource integration, product innovation, and market expansion[34]. - The company is exploring new market opportunities and product development to enhance its competitive position in the pharmaceutical sector[96]. Operational Efficiency - The company emphasizes a commitment to maintaining high standards in manufacturing practices, adhering to GMP and GSP regulations[18]. - The company has constructed intelligent production facilities to enhance automation and efficiency in its manufacturing processes[51]. - The company has established a management academy for ongoing employee training, focusing on various operational and safety standards[143]. - The company has implemented measures to reduce carbon emissions and improve energy efficiency through process improvements[154]. - The company has improved its governance structure and internal control systems to protect shareholder rights[155]. Customer and User Engagement - User data indicates a growth of 25% in the customer base, reaching 1.5 million active users by the end of 2021[18]. - As of the end of the reporting period, the total registered members reached 84.4 million, with 73.33 million purchasing users[39]. - The company has over 73 million transaction members in its e-commerce platform, 康爱多, enhancing its market reach and customer engagement[54]. - 康爱多 has established stable strategic partnerships with over 3,000 industrial enterprises, ensuring a robust supply chain with over 28,000 online SKUs[55]. Financial Management and Governance - The company has established a robust governance structure, complying with relevant laws and regulations, and ensuring fair treatment of all shareholders, especially minority shareholders[111]. - The company has a dedicated internal audit department that supervises the establishment and implementation of internal control systems, ensuring the authenticity and completeness of financial information[112]. - The company has a structured remuneration process for its directors and senior management, ensuring competitive compensation aligned with industry standards[129]. - The company has maintained a high level of attendance at board meetings, with no directors missing two consecutive meetings[134]. - The company has not faced any penalties from securities regulatory agencies in the past three years, indicating compliance and good governance practices[129]. Social Responsibility and Environmental Commitment - The company emphasizes its commitment to social responsibility and has consistently increased tax contributions to local and national governments over the years[157]. - The company adheres to environmental protection laws and regulations, ensuring compliance with pollution control measures[156]. - The company has not reported any significant environmental violations in the past three years[156]. - Environmental protection is a priority for the company, which adheres to higher standards than national regulations and anticipates increased operational costs due to stricter future environmental requirements[105]. Challenges and Risks - The company faces risks from fluctuating national pharmaceutical policies, raw material costs, market competition, and stringent regulatory requirements[104]. - The overall performance of the company was impacted by the transfer of remaining equity stakes in subsidiaries, leading to a net loss of 8.16 million yuan[96]. - The company is actively working to mitigate the potential risks highlighted in the audit report to ensure sustainable and healthy growth[165].